Skip to main content

Pharma News

academics

 

Clinical research courses

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • New biomarker to distinguish between bacterial and viral infections

    A recent study from the Indian Institute of Science (IISc) has identified a set of molecular biomarkers that can be used in the differential diagnosis of acute bacterial and viral infections. These biomarkers are different messenger RNA (mRNA) molecules found in the blood; differences in their levels can detect and predict with high probability if an infection is viral or bacterial.

  • IISc start-up gets regulatory approvals for COVID-19 test

    PathShodh Healthcare, a start-up incubated at the Society for Innovation and Development (SID), Indian Institute of Science (IISc), has made a significant breakthrough in developing a first-of-its-kind, semi-quantitative electrochemical ELISA test for COVID-19 IgM and IgG antibodies.

  • Tulane researchers develop test that detects childhood TB a year ahead of current screenings

    Researchers at Tulane University School of Medicine have developed a highly sensitive blood test that can find traces of the bacteria that causes tuberculosis (TB) in infants a year before they develop the deadly disease, according to a study published in BMC Medicine.

  • Machine learning (AI) accurately predicts cardiac arrest risk

    A branch of artificial intelligence (AI), called machine learning, can accurately predict the risk of an out of hospital cardiac arrest when the heart suddenly stops beating using a combination of timing and weather data, finds research published online in the journal Heart.

    Machine learning is the study of computer algorithms, and based on the idea that systems can learn from data and identify patterns to inform decisions with minimal intervention.

  • Insulin is necessary for repairing olfactory neurons

    Researchers have known for some time that insulin plays a vital role in regeneration and growth in some types of neurons that relay environmental sensory information to our brains, such as sight.

  • Rivaroxaban reduces First and Total Ischemic Events in Patients with Peripheral Artery Disease

    Rivaroxaban, in addition to low dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease who underwent lower extremity revascularization, a procedure to open blocked arteries in the leg.

  • Clopidogrel Superior to Aspirin for Long Term Post Stent Maintenance

    Patients saw 30 percent reduced risk of adverse events after two years of follow up. Clopidogrel outperformed aspirin in what is believed to be the first and largest randomized trial to compare the effectiveness of the two antiplatelet drugs as long term maintenance therapy for patients who had no adverse events after one year of dual antiplatelet therapy following the insertion of a coronary stent.

  • Shilpa Medicare Limited ties up with Dr. Reddys Laboratories Limited for production of Sputnik V vaccine

    Shilpa Biologicals Private Limited, SBPL, has entered into a 3 year DefInitive Agreement with Dr. Reddys Laboratories Limited, DRL, for production supply of the Sputnik V vaccine from its integrated biologics R&D cum manufacturing center at Dharwad, Karnataka.

  • American India Foundation to Set up Oxygen Plants Across 25 Cities in India

    American India Foundation (AIF), on Thursday confirmed, that in collaboration with Paytm, Indian Biogas Association, Foundation For Innovation & Research In Science & Technology and Acquafront Infrastructure Pvt. Ltd., it is set to roll out Oxygen Plants in 25 of the most virus-ravaged cities in the country.

  • Dr. Reddys Laboratories enters into a Voluntary Licensing Agreement with Lilly to Expand Access toCOVID-19 Treatment in India

    Dr. Reddys Laboratories Ltd announced that it has entered into a royalty-free, non-exclusive voluntary  licensing agreement with  Eli Lilly and Company for the manufacture and commercialization of the drug, baricitinib,in India.

Subscribe to Pharma News